A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58-day, Dose-ranging Study of ATI-7505 in Patients with Postprandial Distress Syndrome

Procter & Gamble Pharmaceuticals0 个研究点目标入组 900 人开始时间: 2008年2月7日最近更新: 2012年5月1日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 900

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•At screening:
•Patients are eligible to participate in the study if they:
•a. are willing and able to provide written informed consent;
•b. are male or female between 18 and 75 years of age, inclusive, at Screening;
•c. were diagnosed with PDS at least 6 months prior to screening, OR had onset of 2 or more PDS symptoms at least 6 months prior to screening;
•d. have experienced early satiety or bothersome postprandial fullness repeatedly during the 3 months prior to screening along with one or more of the following symptoms for PDS:
•early satiety,
•bothersome postprandial fullness,
•upper abdominal bloating or distention,
•postprandial nausea,
•excessive belching;
•e. had a normal upper GI endoscopy within the past year (ie, no evidence of erosions or other mucosal abnormalities).
•g. if female, are:
•postmenopausal (at least 1 year without spontaneous menses), or
•surgically sterile (tubal ligation or hysterectomy), or
•using highly effective (ICH 1997) contraception (eg, oral, intramuscular, transdermal, or implanted hormonal contraception [at least 3 months prior to enrollment], sexual partner with non-reversed vasectomy [with azoospermia in 2 tests], 2 independent barrier methods [ie, a combination of 2 of the following methods: condom, diaphragm, or properly applied spermicide], or intra-uterine device). Women who are using contraception will be required to have a pregnancy test (urine) at the Screening, Baseline, Day 29, and Day 58 visits;
•h. have had no significant changes in diet in the 2 months prior to screening and are not planning such changes for the duration of the study;
•i. if taking proton pump inhibitors (PPIs), oral contraceptives, and/or selective serotonin reuptake inhibitors (SSRIs), have been on a stable dose for at least 3 months.
•At randomization:
•Patients are eligible for randomization to a treatment group in the study if they:
•a. have no more than 2 PDS symptom-free days per week during the 2-week run-in period;
•b. have an average PDS-symptom score for either primary symptom (early satiety or
•bothersome postprandial fullness) of greater than mild severity (>2 on the 1-5 Likert scale) for the 2-week run-in period;
•c. have no more than 1 day per week with an EPS-symptom score of greater than moderate severity (>3 on the 1-5 Likert scale) during the 2-week run-in period;
•d. have an average EPS score of, at most, mild severity (=2 on the 1-5 Likert scale) for each week of the 2-week run-in period;
•e. have no more than 3 days per week with heartburn during the 2-week run-in period;
•f. have been at least 70% compliant during the 2-week run-in period with electronic patient reported outcome (ePRO) e-diary entries (at least 10 out of 14 e-diary entries); and
•g. have not missed more than 3 consecutive days of e-diary entries.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patients will be excluded from admission to the 2-week run-in period or randomization to a treatment group if they have/are:
•a. a body mass index (BMI) >32;
•b. current peptic ulcer disease (PUD);
•c. heartburn that occurs >3 times per week;
•d. current Helicobacter pylori (H pylori) infection confirmed by stool sample testing or breath testing, or H pylori eradication therapy within the 6 months prior to screening;
•e. a total Patient Health Questionnaire 15-item Somatic Symptom Severity Scale (PHQ-15) score >17
•f. presence or suspected presence of unstable coronary artery disease, organic gastrointestinal disease, or collagen vascular disease within the 6 months prior to screening;
•g. any alarm symptoms including uninvestigated anemia, rectal bleeding, weight loss, or unresolved fever within the 6 months prior to screening;
•h. taking prohibited medications specified in Section 3.3 within 30 days prior to screening or planning to take prohibited medications at any time during the study;
•i. at screening, a QT interval corrected for heart rate using Bazett’s correction formula (QTcB) >440 msec as determined by the Investigator. The ECG core laboratory will also determine the QTcB and the QT interval corrected for heart rate using Fridericia’s correction formula (QTcF). If either QTcB or QTcF reported by the ECG core laboratory exceeds 440 msec, the patient will not be randomized;
•j. at the Baseline visit, a QTcB >440 msec as determined by the Investigator;
•k. a clinically significant abnormal 12-lead ECG (eg, with evidence of acute or recent
•myocardial infarction or ischemia, rhythm disturbance, or conduction abnormality other than first degree AV block);
•l. a family history of sudden death at age <40 years;
•m. a personal or family history of long QT syndrome;
•n. evidence of current or recent alcohol or drug abuse within the 6 months prior to screening;
•o. participating in another drug or medical device study or use of any investigational drug within 30 days before dosing or planning to use prior to study completion;
•p. a serum potassium, magnesium, or calcium value outside the laboratory reference range at screening or baseline;
•q. a serum aspartate transaminase (AST), alanine transaminase (ALT), or gamma glutamyl transferase (GGT) =3 times the upper limit of the normal laboratory reference range at screening or baseline, or a bilirubin value =2 times the upper limit of the normal laboratory reference range at screening;
•r. diabetes mellitus requiring insulin therapy or oral hypoglycemic agents;
•s. a hemoglobin A1c (Hgb A1c) >7% at screening;
•t. any laboratory value outside the laboratory reference range at screening or baseline that are considered to be clinically significant by the Investigator;
•u. a positive pregnancy test or are nursing or planning a pregnancy during screening, run-in, active treatment, or the follow-up period; or
•v. a history or presence, upon clinical evaluation, of any illness or condition that might impact the safety of study drug administration or evaluability of drug effect based on the Investigator’s discretion.

研究者

发起方

Procter & Gamble Pharmaceuticals

相似试验

进行中（未招募）

不适用

A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58-day, Dose-ranging Study of ATI-7505 in Patients with Postprandial Distress SyndromeMedDRA version: 9.1Level: LLTClassification code 10064536Term: Functional dyspepsiaPostprandial Distress Syndrome

EUCTR2007-005008-41-BEProcter & Gamble Pharmaceuticals900

进行中（未招募）

不适用

EUCTR2007-005008-41-ITProcter & Gamble Pharmaceuticals900

进行中（未招募）

1 期

Testing the Efficacy and Safety of BIO101, for the Prevention of Respiratory Deterioration, in Patients with COVID-19 Pneumonia (COVA study)Confirmed infection with SARS-CoV-2 (COVID-19)MedDRA version: 20.0Level: HLTClassification code 10047465Term: Viral infections NECSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestations

EUCTR2020-001498-63-BEBiophytis S.A.465

进行中（未招募）

1 期

EUCTR2020-001498-63-GBBiophytis S.A.465

进行中（未招募）

1 期

EUCTR2020-001498-63-FRBiophytis S.A.310